UK-based independent SMO, Panthera Biopartners has completed a Series A funding round with Gresham House Ventures as a major investor.

WHY IT MATTERS

Panthera is looking to extend its UK site network by opening a new clinic in Glasgow and expanding existing locations to service higher patient volumes and take forward alliance partnerships across Europe.

The Series A funding will also ensure Panthera has the financial backing to provide pharmaceutical clients and patients with high quality service.  

THE LARGER CONTEXT

Earlier this year, Panthera and Rutherford Health launched an oncology clinical trial network for the development of new cancer treatments. The collaboration is called Panthera@theRutherford and combines Rutherford’s UK network of oncologists and Panthera’s expertise in managing clinical trials.  

ON THE RECORD

Professor John Lyon, chairman of Preston-based Panthera said: “I am pleased that Gresham House Ventures is investing in Panthera and we are delighted to have such a reputable and respected investment house as a shareholder. Despite the challenges faced with Covid, we have built Panthera into a significant player with dedicated sites across the UK in Preston, Manchester and London.”

Brendan Gulston, investment director at Gresham House Ventures, added: “We are very pleased to be able to support such an innovative and experienced team as they look to build a market leading site management organisation.”